{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
INN:zasocitinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Oxisopred is a synthetic corticosteroid that has never been marketed. Information about the current use of this compound is not available.
Status:
Investigational
Source:
NCT03507569: Phase 1 Interventional Completed Autism Spectrum Disorder
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:lingdolinurad [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00000244: Phase 2 Interventional Completed Opioid-Related Disorders
(1994)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:Camlipixant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03363893: Phase 1/Phase 2 Interventional Completed Advanced Solid Malignancies
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00101426: Phase 3 Interventional Completed Diabetic Neuropathy
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Ranirestat (AS-3201, SX-3030, SX-3202) is an oral aldose reductase inhibitor. (-)-enantiomer (AS-3201) is 10 times more potent in inhibition of the aldose reductase and 500 times more potent in the in vivo activity than the corresponding (+)-enantiomer (SX-3202). Ranirestat is being developed by Dainippon Sumitomo Pharma (formerly Dainippon Pharmaceutical) for the treatment of diabetic complications, primarily diabetic neuropathy. Ranirestat is a well-tolerated front-line inhibitor. It reproducibly exhibits some degree of measurable objective beneficial outcomes in diabetic neuropathy.
Status:
Investigational
Source:
NCT04362644: Phase 1 Interventional Recruiting Idiopathic Pulmonary Fibrosis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
BAY85-8102 (widely known as (18)F-DPA-714) is a specific radioligand for the translocator protein (TSPO). TSPO, formerly known as the peripheral benzodiazepine receptor, is dramatically upregulated under pathologic conditions. BAY85-8102 in combination with positron emission tomography imaging participated in phase I clinical trials for investigation of neuroinflammation in Alzheimer's patients. However, this study was terminated early. Clinical pharmacology/efficacy parameters planned in the protocol were not evaluated at the end of the study
